Barriers and facilitators impacting the acceptability and feasibility of pharmacogenomic testing in opioid use disorder treatment

This study looked to identify barriers and facilitators impacting the acceptability and feasibility of PGx testing in opioid use disorder (OUD) treatment. Through open and closed ended surveys with people prescribed medications for OUD (MOUD), medical providers, counselors, clinic staff, and administrators (n=40), we identified barriers and facilitators to the use of PGx to inform methadone prescription. We identified concerns, motivations, reservations, and how participants see PGx potentially impacting them. Focus was placed on ELSI considerations (e.g., through liability [legal implication] or stigma [social and ethical implications]).